ProShare Advisors’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-30,949
| Closed | -$584K | – | 1831 |
|
|
2019
Q3 | $584K | Buy |
30,949
+385
| +1% | +$4.4K | ﹤0.01% | 925 |
|
|
2019
Q2 | $360K | Sell |
30,564
-2,881
| -9% | -$34.9K | ﹤0.01% | 1151 |
|
|
2019
Q1 | $457K | Buy |
33,445
+4,143
| +14% | +$53.7K | ﹤0.01% | 1048 |
|
|
2018
Q4 | $300K | Sell |
29,302
-5,652
| -16% | -$72.4K | ﹤0.01% | 1156 |
|
|
2018
Q3 | $582K | Sell |
34,954
-1,233
| -3% | -$22.3K | ﹤0.01% | 1041 |
|
|
2018
Q2 | $572K | Sell |
36,187
-3,283
| -8% | -$49.9K | ﹤0.01% | 1051 |
|
|
2018
Q1 | $501K | Sell |
39,470
-6,446
| -14% | -$93.2K | ﹤0.01% | 1095 |
|
|
2017
Q4 | $526K | Buy |
45,916
+3,419
| +8% | +$38.2K | ﹤0.01% | 1108 |
|
|
2017
Q3 | $521K | Buy |
42,497
+12,452
| +41% | +$130K | ﹤0.01% | 948 |
|
|
2017
Q2 | $344K | Sell |
30,045
-2,251
| -7% | -$41.6K | ﹤0.01% | 1101 |
|
|
2017
Q1 | $672K | Sell |
32,296
-8,457
| -21% | -$187K | 0.01% | 895 |
|
|
2016
Q4 | $848K | Buy |
40,753
+3,805
| +10% | +$98.9K | 0.01% | 851 |
|
|
2016
Q3 | $1.21M | Sell |
36,948
-5,978
| -14% | -$182K | 0.02% | 629 |
|
|
2016
Q2 | $1.07M | Buy |
42,926
+7,675
| +22% | +$208K | 0.01% | 693 |
|
|
2016
Q1 | $863K | Sell |
35,251
-3,225
| -8% | -$74.7K | 0.01% | 756 |
|
|
2015
Q4 | $1.27M | Buy |
38,476
+3,058
| +9% | +$103K | 0.02% | 652 |
|
|
2015
Q3 | $1.16M | Buy |
35,418
+2,493
| +8% | +$106K | 0.02% | 630 |
|
|
2015
Q2 | $1.74M | Buy |
32,925
+443
| +1% | +$16.1K | 0.02% | 556 |
|
|
2015
Q1 | $937K | Buy |
32,482
+10,361
| +47% | +$284K | 0.01% | 873 |
|
|
2014
Q4 | $643K | Buy |
+22,121
| New | +$397K | 0.01% | 1086 |
|
ProShare Advisors's ALDR Position: Q4 2019 in Review
ProShare Advisors sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 30,949 shares — an estimated $584K sold.
ProShare Advisors first reported a position in ALDR in Q4 2014 and held it in 20 quarters. The position peaked at $1.74M in Q2 2015. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- ProShare Advisors reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- ProShare Advisors sold 30,949 Alder Biopharmaceuticals shares in Q4 2019, an estimated $584K.
- ProShare Advisors first reported a position in Alder Biopharmaceuticals in Q4 2014 and held it in 20 quarters.
- ProShare Advisors's Alder Biopharmaceuticals position peaked at $1.74M in Q2 2015.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on ProShare Advisors's 13F filing for Q4 2019, filed 12 Feb 2020.